The European Guidelines for Treatment of HIV Infected Adults in Europe (European AIDS Clinical Society, version 11.0 - October 2021).https://eacs.sanfordguide.com
Saag MS, Gandhi RT, Hoy JF, et al; Antiretroviral drugs for treatment and prevention of HIV infection in adults:2020 Recommendations of the international antiretroviral society-USA panel. JAMA. 324(16):1651-1669. 2020.
Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119-29. 2002.
Sterling TR, Chaisson RE, J. Keruly J, et al. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 188:1659-65. 2003.
Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 18:89-97. 2004.
Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286:2568-77. 2001.
Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-70. 1996.
Moore RD and Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44:441-6. 2007.
Lok J, Bosch R, Benson C, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 24: 1867-76. 2010.
Severe P, Juste MAJ, Ambroise A, et al. Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. N Engl J Med 363:257-65. 2010.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360:1815-26. 2009.
Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373:1352-63. 2009.
Funk MJ, Fusco JS, Cole SR et al. Timing of HAART initiation and clinical outocomes in HIV-1 seroconverters. Arch Intern Med 171 (17): 1560-9. 2011.
Grulich AE, van Leeuwen MT, Falster MO, at al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67. 2007.
Long JL, Engels EA, Moore RD, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 22:489-96. 2008.
Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-36. 2008.
El-Sadr WM, Lundgren JD, Neaton JD, at al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283-96. 2006.
Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166:1632-41. 2006.
Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723-35. 2007.
Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 197:1145-55. 2008.
Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197:1133-44. 2008.
Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 23:1743-53. 2009.
Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 46:72-7. 2007.
Jaen A, Esteve A, Miro JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 47:212-20. 2008.
INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373: 795-807. 2015.
TEMPRANO ANRS Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 373: 808-22. 2015.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 365:493-505. 2011.
Rodger AJ, Cambiano V, Bruun T, et al. ; PARTNER Study Group. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016 Jul 12;316(2):171-81.
Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-e447.
Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization. September 2015.
Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 4:e5575. 2009.